Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the ketolide telithromycin: Results from the PROTEKT surveillance study (1999-2000)

Chemotherapy

Volumn 50, Issue 3, 2004, Pages 143-151

  Reinert, R R ^a   Rodloff, A C ^b   Halle, E ^c   Baer, W ^d   Beyreiss, B ^d   Seifert, H ^e   Wichelhaus, T A ^f   Maass, M ^g   Mehl, M ^h  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Institute of Medical Microbiology   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g UNIVERSITY OF LÜBECK   (Germany)

^h Helios Hospital   (Germany)

Author keywords

Antimicrobial resistance; Germany; PROTEKT; Respiratory tract pathogens

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAMASE; CEFACLOR; CEFIXIME; CEFPODOXIME; CEFUROXIME; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; GERMANY; HAEMOPHILUS INFLUENZAE TYPE A; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; GERMANY; HAEMOPHILUS INFLUENZAE; HUMANS; KETOLIDES; LONGITUDINAL STUDIES; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; MULTICENTER STUDIES; PENICILLIN RESISTANCE; POPULATION SURVEILLANCE; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 3242805123     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077889     Document Type: Article

References (28)

1. Felmingham D, Grüneberg RN: The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203.
2. Thornsberry C, Sahm DF: Antimicrobial resistance in respiratory tract pathogens: Results of an international surveillance study. Chemotherapy 2000;46:15-23.
3. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347-382.
4. Felmingham D, Washington J: Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the Alexander Project 1992-1996. J Chemother 1999;11(suppl 1):5-21.
5. Mandell LA: Community-acquired pneumonia. Etiology, epidemiology, and treatment. Chest 1995;108(suppl 2):35-42.
6. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R: The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-837.
7. Fenoll A, Jado I, Vicioso D, Perez A, Casal J: Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: Update (1990 to 1996). J Clin Microbiol 1998;36:3447-3454.
8. Geslin P, Frémaux A, Sissia G, Spicq C: Streptococcus pneumoniae: Serotypes, invasive and antibiotic resistant strains. Current situation in France. Presse Med 1998;27(suppl 1):21-27.
9. Marton A, Gulyas M, Munoz R, Tomasz A: Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J Infect Dis 1991;163:542-548.
10. Reinert RR, Queck A, Kaufhold A, Kresken M, Lütticken R: Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992-1994. Clin Infect Dis 1995;21:1398-1401.
11. Richard MP, Aguado AG, Mattina R, Marre R: Sensitivity to sparfloxacin and other antibiotics of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: A European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance. J Antimicrob Chemother 1998;41:207-214.
12. Schito GC, Debbia EA, Marchese A: The evolving threat of antibiotic resistance in Europe: New data from the Alexander Project. J Antimicrob Chemother 2000;46(suppl T1):3-9.
13. Reinert RR, Simic S, Al-Lahham A, Reinert S, Lemperle M, Lütticken R: Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: Results of a national surveillance study. J Clin Microbiol 2001;39:1187-1189.
14. Reinert RR, Al-Lahham A, Lemperle M, Tenholte C, Briefs C, Haupts S, Gerards HH, Lütticken R: Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002;49:61-68.
15. Felmingham D: Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin Microbiol Infect 2001;7(suppl 3):2-10.
16. Balfour JA, Figgitt DF: Telithromycin. Drugs 2001;61:815-831.
17. Felmingham D: The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002;50(suppl S1):1-7.
18. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Sensitivity Testing, ed 12. Supplemental Tables M100-S12. Wayne, NCCLS, 2002.
19. Farrell DJ, Morrissey I, Bakker S, Felmingham D: Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization. J Antimicrob Chemother 2001;48:541-544.
20. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN: Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):81-93.
21. Čižman M, Pokorn M, Seme K, Oražem A, Paragi M: The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J Antimicrob Chemother 2001;47:475-457.
22. Granizo JJ, Aguilar L, Casal J, García-Rey C, Dal-Ré R, Baquero F: Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979.1997). J Antimicrob Chemother 2000;46:767-773.
23. Editorial: Pneumokokken-Impfung tritt in den USA einen Siegeszug an. Ärztl Prax 2002:54:8.
24. Farrell DJ, Douthwaite S, Morrissey I, Bakker S, Poehlsgaard J, Jakobsen L, Felmingham D: Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob Agents Chemother 2003;47:1777-1783.
25. Jones ME, Blosser-Middleton RS, Critchley IA, Thornsberry C, Sahm DF, Yamakita J, Akasaki M, Karlowsky JA: The activity of levofloxacin and comparator agents against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999 and 2000. Chemotherapy 2002;48:232-237.
26. Hoban D, Palatnick L, Weshnoweski B, Cox L, Balko T, Karlowsky J, Zhanel G: The novel ketolide HMR 3647 is highly active against worldwide isolates of Streptococcus pneumonia and Streptococcus pyogenes (abstract). 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, Barcelona, January 1998.
27. Bozdogan B, Appelbaum PC, Kelly LM, Hoellman DB, Tambic-Andrasevic A, Drukalska L, Hryniewicz W, Hupkova H, Jacobs MR, Kolman J, Konkoly-Thege M, Miciuleviciene J, Pana M, Setchanova L, Trupl J, Urbaskova P: Activity of telithromycin compared with seven other agents against 1,039 Streptococcus pyogenes pediatric isolates from ten centers in central and eastern Europe. Clin Microbiol Infect 2003;9:741-745.
28. Reinert RR, Lütticken R, Briefs C, Neuberger N, Lemperle M, Al-Lahham A: Antibiotic resistance of Streptococcus pyogenes and Streptococcus pneumoniae strains isolated from RTI of outpatients in Germany, 2000.01 (abstract). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 2001.